References
- Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm 2006;62:3–16
- Kawabata Y, Wada K, Nakatani M, et al. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm 2011;420:1–10
- Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007;59:631–44
- Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008;364:64–75
- Gao L, Zhang DR, Chen MH, et al. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm 2008;355:321–7
- Hecq J, Deleers M, Fanara D, et al. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm 2006;64:360–8
- Moschwitzer J, Muller RH. Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur J Pharm Biopharm 2006;62:282–7
- Ganta S, Paxton JW, Baguley BC, Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm 2009;367:179–86
- Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discovery 2004;3:785–96
- Al-Anati L, Essid E, Reinehr R, Petzinger E. Silibinin protects OTA-mediated TNF-alpha release from perfused rat livers and isolated rat Kupffer cells. Mol Nutr Food Res 2009;53:460–6
- Jayaraj R, Deb U, Bhaskar AS, et al. Hepatoprotective efficacy of certain flavonoids against microcystin induced toxicity in mice. Environ Toxicol 2007;22:472–9
- Wu JW, Lin LC, Hung SC, et al. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. Pharm Biomed Anal 2007;45:635–41
- Sun W, Tian W, Zhang Y, et al. Effect of novel stabilizers – cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals. Nanomedicine: NBM 2012;8:460–7
- Ricklig B, Hnas B, Kramarczyk R, et al. Two high-performance liquid chromatographic assays for the determination of free and total silibinin diastereomers in plasma using column switching with electrochemical detection and reversed-phase chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 1995;670:267–77
- Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev 2011;63:456–69
- Lee J, Choi JY, Park CH. Characteristics of polymers enabling nanocomminution of water-insoluble drugs. Int J Pharm 2008;355:328–36
- Patel GV, Patel VB, Pathak A, Rajput SJ. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. Drug Dev Ind Pharm 2014;40:80–91
- Sun W, Mao S, Shi Y, et al. Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci 2011;100:3365–73
- Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006;312:179–86
- Muller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm 2002;237:151–61
- Gao Y, Li Z, Sun M, et al. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev Ind Pharm 2010;36:1225–34
- Xu Y, Wang Y, Li XM, et al. Study on the release of fenofibrate nanosuspension in vitro and its correlation with in situ intestinal and in vivo absorption kinetics in rats. Drug Dev Ind Pharm 2013. [Epub ahead of print]. doi:10.3109/03639045.2013.794828
- Dodiya S, Chavhan S, Korde A, Sawant KK. Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies. Drug Dev Ind Pharm 2013;39:733–43